Development of pan-influenza inhibitors targeting the PA endonuclease from the viral replication complex
Ended Definitive Contract Awarded
- Contract number
- 75N93025C00038
- Awardee
-
Cocrystal Pharma, Inc. UEI UY8UDESGRJ17
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $498,199
Award facts
- Opportunity
-
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals Pre-Solicitation · PHS20251 · Posted Jul 18, 2024
- Contract value 100% obligated
- $498,199.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 4 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Bothell, WA 98011, USA
- Research
- SBIR Program Phase I Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the U.S. Department of Health and Human Services, to Cocrystal Pharma, Inc. The $498,199 fixed-price contract is for the development of pan-influenza inhibitors targeting the PA endonuclease from the viral replication complex. This research is being conducted under the SBIR program, which aims to stimulate technological innovation, strengthen the role of small businesses in federal research, and increase commercialization of innovations. The original solicitation was a pre-solicitation notice for the DHHS/NIH/CDC SBIR Program, which covered a wide range of research topics across various NIH institutes and CDC centers, including drug development, diagnostics, medical devices, and digital health technologies.
Quick answers
Who was awarded contract 75N93025C00038?
75N93025C00038 was awarded to Cocrystal Pharma, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 29, 2025.
How much is contract 75N93025C00038 worth?
The government has obligated $498,199 on 75N93025C00038.
Was contract 75N93025C00038 competed?
The extent of competition for 75N93025C00038 was full and open competition after exclusion of sources. The government received 4 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award